KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow: 2018-2025

Historic Net Cash Flow for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $6.4 million.

  • Esperion Therapeutics' Net Cash Flow rose 114.32% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 274.91%. This contributed to the annual value of $62.5 million for FY2024, which is 247.00% up from last year.
  • Per Esperion Therapeutics' latest filing, its Net Cash Flow stood at $6.4 million for Q3 2025, which was up 122.35% from -$28.6 million recorded in Q2 2025.
  • Esperion Therapeutics' Net Cash Flow's 5-year high stood at $144.4 million during Q1 2024, with a 5-year trough of -$87.0 million in Q1 2021.
  • Moreover, its 3-year median value for Net Cash Flow was -$23.6 million (2023), whereas its average is -$2.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 2,299.20% in 2022, then surged by 616.93% in 2024.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Net Cash Flow stood at $105.2 million in 2021, then slumped by 180.43% to -$84.6 million in 2022, then spiked by 61.49% to -$32.6 million in 2023, then surged by 100.14% to $44,000 in 2024, then soared by 114.32% to $6.4 million in 2025.
  • Its Net Cash Flow stands at $6.4 million for Q3 2025, versus -$28.6 million for Q2 2025 and -$30.1 million for Q1 2025.